Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000556 |
Recruitment Status :
Completed
First Posted : October 28, 1999
Last Update Posted : March 25, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Arrhythmia Atrial Fibrillation Cardiovascular Diseases Heart Diseases | Drug: amiodarone Drug: sotalol Drug: propafenone Drug: flecainide Drug: quinidine Drug: moricizine Drug: disopyramide Drug: procainamide Drug: adrenergic beta antagonists Drug: verapamil Drug: diltiazem Drug: digoxin Procedure: catheter ablation Device: pacemaker, artificial | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Primary Purpose: | Treatment |
Study Start Date : | March 1995 |
Study Completion Date : | September 2002 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years to 100 Years (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000556
OverallOfficial: | H. Greene | Statistics and Epidemiology Research Corporation (S.E.R.C.) |

NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00000556 |
Other Study ID Numbers: |
100 |
First Posted: | October 28, 1999 Key Record Dates |
Last Update Posted: | March 25, 2016 |
Last Verified: | November 2005 |
Atrial Fibrillation Cardiovascular Diseases Heart Diseases Arrhythmias, Cardiac Pathologic Processes Quinidine Digoxin Amiodarone Verapamil Sotalol Flecainide Propafenone Procainamide Moricizine Disopyramide |
Diltiazem Adrenergic beta-Antagonists Adrenergic Agents Anti-Arrhythmia Agents Cardiotonic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vasodilator Agents Potassium Channel Blockers Membrane Transport Modulators Sodium Channel Blockers Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 Enzyme Inhibitors |